Silence Therapeutics plc (NASDAQ:SLN) Receives $54.75 Average Price Target from Brokerages

Silence Therapeutics plc (NASDAQ:SLN) has been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $54.75.

A number of brokerages have commented on SLN. Morgan Stanley reaffirmed an “overweight” rating and set a $49.00 target price on shares of Silence Therapeutics in a report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, January 29th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. Finally, William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SLN. GAMMA Investing LLC increased its holdings in Silence Therapeutics by 609.2% during the 4th quarter. GAMMA Investing LLC now owns 6,092 shares of the company’s stock worth $42,000 after purchasing an additional 5,233 shares during the period. Values First Advisors Inc. purchased a new stake in Silence Therapeutics in the 3rd quarter valued at $56,000. China Universal Asset Management Co. Ltd. purchased a new position in Silence Therapeutics in the 4th quarter valued at $69,000. FNY Investment Advisers LLC acquired a new position in Silence Therapeutics in the 4th quarter valued at $120,000. Finally, Verition Fund Management LLC purchased a new position in Silence Therapeutics during the 3rd quarter worth $207,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

Shares of NASDAQ:SLN opened at $5.61 on Friday. Silence Therapeutics has a 1 year low of $4.82 and a 1 year high of $27.72. The company has a market cap of $167.90 million, a P/E ratio of -3.57 and a beta of 1.08. The stock’s fifty day moving average price is $6.52 and its 200-day moving average price is $13.52.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.